Last reviewed 2026-04-23 · How we verify

Actiq® 400 µg transmucosally

INSYS Therapeutics Inc · Phase 1 active Small molecule

Actiq® 400 µg transmucosally is a opioid analgesic Small molecule drug developed by INSYS Therapeutics Inc. It is currently in Phase 1 development for Breakthrough cancer pain. Also known as: fentanyl citrate.

Fentanyl acts by binding to opioid receptors, primarily mu-opioid receptors, in the central nervous system to produce analgesia and euphoria.

Fentanyl acts by binding to opioid receptors, primarily mu-opioid receptors, in the central nervous system to produce analgesia and euphoria. Used for Breakthrough cancer pain.

At a glance

Generic name	Actiq® 400 µg transmucosally
Also known as	fentanyl citrate
Sponsor	INSYS Therapeutics Inc
Drug class	opioid analgesic
Target	mu-opioid receptor
Modality	Small molecule
Therapeutic area	Pain Management
Phase	Phase 1

Mechanism of action

Fentanyl is a potent synthetic opioid that mimics the effects of endogenous opioids. It binds with high affinity to mu-opioid receptors, leading to inhibition of nociceptive transmission and modulation of pain perception.

Approved indications

Breakthrough cancer pain

Common side effects

Nausea
Vomiting
Dizziness

Key clinical trials

Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Actiq® 400 µg transmucosally CI brief — competitive landscape report
Actiq® 400 µg transmucosally updates RSS · CI watch RSS
INSYS Therapeutics Inc portfolio CI

Frequently asked questions about Actiq® 400 µg transmucosally

What is Actiq® 400 µg transmucosally?

Actiq® 400 µg transmucosally is a opioid analgesic drug developed by INSYS Therapeutics Inc, indicated for Breakthrough cancer pain.

How does Actiq® 400 µg transmucosally work?

Fentanyl acts by binding to opioid receptors, primarily mu-opioid receptors, in the central nervous system to produce analgesia and euphoria.

What is Actiq® 400 µg transmucosally used for?

Actiq® 400 µg transmucosally is indicated for Breakthrough cancer pain.

Who makes Actiq® 400 µg transmucosally?

Actiq® 400 µg transmucosally is developed by INSYS Therapeutics Inc (see full INSYS Therapeutics Inc pipeline at /company/insys-therapeutics-inc).

Is Actiq® 400 µg transmucosally also known as anything else?

Actiq® 400 µg transmucosally is also known as fentanyl citrate.

What drug class is Actiq® 400 µg transmucosally in?

Actiq® 400 µg transmucosally belongs to the opioid analgesic class. See all opioid analgesic drugs at /class/opioid-analgesic.

What development phase is Actiq® 400 µg transmucosally in?

Actiq® 400 µg transmucosally is in Phase 1.

What are the side effects of Actiq® 400 µg transmucosally?

Common side effects of Actiq® 400 µg transmucosally include Nausea, Vomiting, Dizziness.

What does Actiq® 400 µg transmucosally target?

Actiq® 400 µg transmucosally targets mu-opioid receptor and is a opioid analgesic.

Related

Drug class: All opioid analgesic drugs
Target: All drugs targeting mu-opioid receptor
Manufacturer: INSYS Therapeutics Inc — full pipeline
Therapeutic area: All drugs in Pain Management
Indication: Drugs for Breakthrough cancer pain
Also known as: fentanyl citrate
Compare: Actiq® 400 µg transmucosally vs similar drugs
Pricing: Actiq® 400 µg transmucosally cost, discount & access